Association of time from last known well to alteplase administration and outcomes in acute stroke.


Journal

The American journal of emergency medicine
ISSN: 1532-8171
Titre abrégé: Am J Emerg Med
Pays: United States
ID NLM: 8309942

Informations de publication

Date de publication:
12 2021
Historique:
received: 22 04 2021
revised: 08 06 2021
accepted: 09 07 2021
pubmed: 7 8 2021
medline: 21 12 2021
entrez: 6 8 2021
Statut: ppublish

Résumé

In order to determine if time from onset to treatment time (OTT) to alteplase (tPA) administration is associated with improved outcomes in acute ischemic stroke, we performed a retrospective analysis of all acute ischemic stroke patients who received tPA at our hospital. We performed a retrospective review of our Get With the Guidelines® stroke data to determine OTT was associated with either 1.) modified Rankin scale (mRS) at 90 days or 2.) in hospital hemorrhagic conversion. OTT was examined both as a continuous variable in univariate and multivariate analyses as well as a dichotomous variable with a cutoff of 60 min. We controlled for demographic characteristics, 24 medical history issues, receipt of thrombectomy, and NIH stroke scale at admission. We included 166 patients with data for mRS at 90 days after discharge and 302 patients for hemorrhagic conversion in hospital. In all analyses, there was no difference between OTT in either outcome. Predictors of improved mRS at 90 days included NIH Stroke Scale at admission, age, and lack of hypertension. The only significant predictors for hemorrhagic conversion was NIH stroke scale at admission. Our small, retrospective data shows no association between OTT and either hemorrhagic conversion or mRS at 90 days. This data lends support that time may not be the ideal indicator for identifying patients who will benefit from tPA administration.

Identifiants

pubmed: 34358798
pii: S0735-6757(21)00599-4
doi: 10.1016/j.ajem.2021.07.033
pii:
doi:

Substances chimiques

Fibrinolytic Agents 0
Tissue Plasminogen Activator EC 3.4.21.68

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

126-128

Informations de copyright

Copyright © 2021 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest Regarding “Association of Time from Last Known Well to Alteplase Administration and Outcomes in Acute Stroke”, Dr. Davis has no conflicts of interest, financial or other, to declare.

Auteurs

Joshua Davis (J)

Dr. Davis is an Emergency Medicine Physician at Vituity, Clinical Instructor at the University of Kansas School of Medicine, Wichita, KS, United States of America. Electronic address: jjvwd@udel.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH